Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”Eptacog Beta Beyond Labels: Spanish Real-World Evidence
- 8 patients | 2 Madrid centres | 3 rare bleeding disorders
- On-Label Treatments (HA + Inhibitors; n=4)
- 3/4 on concurrent emicizumab (excluded from PERSEPT trials)
- Dosing: 75 µg/kg
- Breakthrough control + thrombotic safety
- Severe iliopsoas haematoma: 70 infusions → complete resolution, zero thrombotic events
Off-Label Treatments (n=4)
- Factor VII deficiency (n=3): Perioperative surgery with 15–20 µg/kg—excellent haemostasis, zero bleeding complications
- Steroid-refractory acquired haemophilia (n=1): High-titre inhibitor case reflects poor-prognosis disease biology
No Safety Signal: Zero thrombotic/thromboembolic complications across all patients
As emicizumab, concizumab, marstacimab and fitusiran transform prophylaxis of haemophilia, eptacog beta emerges as a versatile rescue therapy.
This real-world experience expands treatment paradigms beyond current labels—pending validation from further studies.
Congratulations to the authors!”
Read the full article here.
Article: Real-World Experience with Eptacog Beta for On-Label and Off-Label Indications: The Spanish Experience
Authors: Jose Manuel Martin de Bustamante, María Isabel Rivas-Pollmar, Natalia Acedo, Nora Butta, Victor Jimenez-Yuste, Maria Teresa Álvarez-Román
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications
-
Jan 6, 2026, 09:52Antoine Francis: Plasma is Not Just Another Component of Healthcare…
-
Jan 6, 2026, 09:45Hurry to Join EHC Youth Leadership Workshop 2026
-
Jan 6, 2026, 09:41Andrew Petrosoniak Makes It to N1 on EMCases Best of 2025!
-
Jan 6, 2026, 09:35Sara Ng: Moving Beyond Management to Stewardship – “Advancing Anticoagulation Stewardship” Released by NQF
-
Jan 6, 2026, 09:30Wolfgang Miesbach: Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B
-
Jan 6, 2026, 09:09Abdulrahman Nasiri: A New Perspective on Avatrombopag in Aplastic Anemia